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summAry – fifty years ago, robson introduced radical nephrectomy (rn) setting the gold 
standard for treating kidney tumors. experience has shown that partial nephrectomy (Pn) can 
be equally effective with the advantages of preserving kidney function and avoiding unnecessary 
nephrectomies for benign tumors. The purpose of this report is to demonstrate the evolution of 
clinical presentation and choice of treatment for patients with kidney tumors at our department, 
emphasizing changes in the Pn utilization trends. Clinical data were abstracted for the years 2002, 
2007 and 2012. we assessed annual trends for changes in the choice of operative treatment related 
to tumor size, pathologic stage and diagnosis. during the study, there was an increase in the share 
of T1 tumors, from 46.6% in 2002 to 69.8% in 2012. The rate of Pn increased more than ten-fold, 
from 2.7% in 2002 to 31.7% in 2012. The annual rates of Pn for T1 tumors increased even more, 
from 6.6% in 2002 to 46.7% in 2012. opposite to rn group, there was an increase in the mean 
tumor size in Pn group (from 1.8 cm in 2002 to 3.9 cm in 2012). The rate of rn for benign tumors 
was reduced impressively from 85.7% in 2002 to 23.1% in 2012. our data argue strongly that Pn 
should be expanded and not restricted. robson’s principles have been partially deserted over the last 
decade; however, proving that Pn is superior to rn still remains to be elucidated.
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Introduction
renal cell carcinoma (rCC) is most lethal of all 
urologic cancers and surgery is still the only curative 
therapeutic approach. historically, surgery has been 
mostly responsible for improvement in survival of pa-
tients with localized rCC. in 1963, robson described 
radical nephrectomy (rn) as a method to treat rCC, 
which remained the procedure of choice for treating 
solid kidney tumors for the remainder of the century1. 
however, in the late 1970s, nephron sparing surgery 
(nss) was introduced as a method that preserved 
healthy kidney tissue and as such broke all the prin-
ciples of radical surgery set by robson. Partial neph-
rectomy (Pn) allowed for healthy kidney tissue to be 
salvaged but concern about a higher incidence of re-
lapse was a valid argument for those who preferred 
rn. subsequent research has shown that, for tumors 
up to a certain stage, Pn can be performed with the 
same survival rate as rn. in 2002, the upper limit for 
resectable tumors was set at 4 cm in diameter (stage 
T1a). however, recent studies have shown that the ac-
ceptable limit is 7 cm (stage T1) and in some cases 
even 10 cm (stage T2)2. during the last decade, Pn 
has emerged as a standard treatment for small renal 
masses offering oncologic control equivalent to rn 
with preservation of renal function and evidence for 
improved survival. The size of resectable tumors has 
increased over years, showing that the boundaries of 
nss are constantly being pushed forward.
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The purpose of this report is to evaluate our expe-
rience in surgical management of solid kidney tumors. 
we retrospectively evaluated postoperative data of pa-
tients having undergone Pn or rn for kidney tumors 
in our institution. Changes and advances in patient 
selection criteria and type of surgical management 
are evaluated and discussed emphasizing the signifi-
cance of changes in Pn utilization trends during the 
observation period. recent literature on the topic is 
reviewed and discussed.
Material and Methods
we retrospectively analyzed preoperative and early 
postoperative clinical data of patients treated surgi-
cally for solid kidney tumors at our institution (de-
partment of urology, sestre milosrdnice university 
hospital Center, Zagreb, Croatia). A computerized 
database was created and data abstracted directly 
from the records at our department for the years 2002, 
2007 and 2012. from our database, we identified pa-
tients that had undergone surgery for solid kidney 
tumors by Pn or rn and simple nephrectomy. for 
study purposes, patients undergoing simple nephre-
ctomy were included in the rn group. Patients with 
nonfunctional kidneys, infections and trauma where 
excluded from analysis even though nephrectomy was 
performed. The information abstracted and entered 
included the date of surgery, type of surgery, patient 
age, tumor size, final pathologic diagnosis and stage. 
Patients were staged according to the 2010 Tnm 
staging criteria3. Clinical and pathologic data were 
analyzed and compared for annual changes over the 
observation period. descriptive statistics and time-
flow charts were used to analyze trends over time.
Results
The mean patient age at diagnosis was 61.2 years 
in 2002. it gradually increased yearly to reach 61.9 
(overall range 27 to 97) years in 2012. The mean age 
of patients undergoing Pn and rn was 72.6 (range 
35 to 86) years and 60.1 (range 27 to 87) years, re-
spectively.
The annual frequency of surgical interventions in-
creased markedly at our department, from 73 to 126 
during the observation period (fig. 1). 
The distribution of postoperative tumor stages 
with time is shown in figure 2. Annual distributions 
of postoperative stages demonstrate stage migration 
towards T1 disease. Annual rates of postoperative 
pT1 stages were 46.6%, 55% and 69.8% in the obser-
vation period. The rates of pT2 disease decreased from 
21% in 2002 to 15.8% in 2012. As expected, the con-
Fig. 1. Number of patients undergoing surgery for all 
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tributions of pT3 and pT4 disease decreased steadily 
over years.
The annual rates of rn and Pn utilization are il-
lustrated in figure 3. The proportion of patients with 
kidney tumors treated with Pn increased markedly 
throughout the study and ranged from 2.7% in 2002 
to 31.7% in 2012.
The annual rates of patients undergoing Pn for T1 
tumors only increased even more, from 6.6% in 2002 
to 46.7% in 2012 (fig. 4). The annual utilization trends 
of Pn and rn for T1a and T1b subgroups of tumors 
are illustrated in figures 5 and 6. for T1a (<4 cm) tu-
mors, Pn was performed in 7.7%, 20.7% and 55.6% of 
patients in the observation period. on the other hand, 
the rates of Pn for larger T1b (4-7 cm) tumors were 
only 5.6%, 15.4% and 16.7%, respectively.
for patients treated with rn, the mean tumor size 
was 6.8 cm, 6.1 cm and 6.6 cm in the observation pe-
riod (range from 1.4 to 19 cm) (fig. 7). As expected, 
the mean tumor size for patients treated with Pn in-
creased gradually from 1.8 cm in 2002 to 3.9 cm in 
2012 (range from 1.1 to 9.5 cm) (fig. 7), indicating 
improvement in preoperative imaging assessment and 
surgical technique. 
figure 8 illustrates annual rates of patients un-
dergoing rn and Pn for benign tumors. The rate of 
patients undergoing unnecessary rn for benign tu-
mors was reduced impressively from 85.7% in 2002 
to 23.1% in 2012. in 2002, seven (9.5%) patients un-
derwent surgery for benign tumors, whereas in 2007 
and in 2012 there were 13 such cases each year (13% 
and 10.3%, respectively). The histopathologic diagno-
sis showed only two types of solid tumors (excluding 
simple cysts) with an almost equal distribution, i.e. 
17 (51.5%) patients with angiomyolipomas and 16 
(48.5%) patients with oncocytomas.
Fig. 4. Annual rates of patients undergoing radical neph-
rectomy and partial nephrectomy for T1 kidney tumors.
























Fig. 5. Annual rates of patients undergoing radical 
nephrectomy and partial nephrectomy for T1a kidney 
tumors.
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Fig. 6. Annual rates of patients undergoing radical neph-
rectomy and partial nephrectomy for T1b kidney tumors.
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Fig. 7. Mean tumor size in patients undergoing radical ne-
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Discussion
renal cell carcinoma is the third most frequent 
urologic cancer that accounts for 2%-3% of all adult 
malignancies4. Adenocarcinoma is the most preva-
lent histologic subtype, responsible for approximately 
85% of renal tumors5. Currently, up to 40% of kidney 
neoplasms are detected incidentally because of the 
widespread use of imaging technologies5. Today, we 
are looking at the downward migration toward the 
diagnoses of asymptomatic, incidental, smaller and 
lower-stage lesions.
since the publication of robson’s landmark article 
in 1969, and due to concerns about incomplete tumor 
excision, local recurrence, microscopic satellite tumors 
and multifocality, rn had remained the gold standard 
for the treatment of localized rCCs for almost three 
decades6. This procedure was questioned in the 1980s 
by several reports demonstrating favorable results with 
nss for imperative indications7. initial applications of 
nss in the modern era were limited to absolute indica-
tions such as bilateral renal masses or tumor in a func-
tionally or anatomically solitary kidney. during the last 
decade, elective Pn has supplanted rn as the treat-
ment of choice for small renal masses with comparable 
oncologic outcomes and benefits of renal preservation. 
until recently, 4 cm (T1a tumor) was considered as a 
cut-off size for Pn. Two landmark studies established 
4 cm as the upper limit below which Pn could be indi-
cated; for elective indications, nss for T1a tumors pro-
vided recurrence free and long-term survival rates simi-
lar to those observed after radical surgery8. based on 
these data, the cut-off limit of 4 cm was arbitrarily set 
to delineate the indications for Pn. Those figures were 
the scientific background for the 2002 Tnm staging 
system update and this observation has, in part, led to 
substratification of the stage T1 classification into T1a 
and T1b. The advantages of nss over rn for tumors 
up to 4 cm in diameter, such as lower mortality and 
lesser risk of developing renal insufficiency and cardio-
vascular disease have been reported 9-11.
novel developments and improvements in radio-
logic imaging, such as ultrasonography, computed 
tomography (CT), and magnetic resonance imag-
ing have succeeded in diagnosing small renal masses 
found incidentally during investigation of unrelated 
complaints, which have allowed for a shift towards 
a more organ-preserving approach12,13. our findings 
show an increased number of diagnosed patients with 
a migration towards lower stages during the study pe-
riod, with the majority of diagnosed tumors today be-
ing discovered at T1b stage or less, which allowed for 
greater application of Pn at our institution.
The utilization rates of Pn at tertiary care cen-
ters among patients with localized rCC ranged from 
33% to 52%14. similarly, the proportion of patients 
treated with Pn in our institution increased mark-
edly throughout the study and ranged from 2.7% in 
2002 to 32.0% in 2012. At our institution, a ten-fold 
increase was recorded from 2002 to 2012 in choosing 
Pn as the method of treatment, showing only partial 
abandonment of robson’s principles of radical surgery 
in selected patients. Among patients with tumors less 
than 4 cm (T1a), 7.1% underwent Pn in 2002 com-
pared with 55.6% in 2012. This relative increase is 
mirroring the increase in the incidence of the more 
organ-confined disease described during a similar in-
terval and highlighting the growing acceptance of Pn 
as a viable therapeutic option. interestingly, the rates 
of Pn for larger T1b (4-7 cm) tumors at our insti-
tution were not so high (from 5.6% in 2002 to 17% 
in 2012). Therefore, when confronted with larger and 
more complex tumors, rn is still the preferred treat-
ment in our institution. Collectively, these data pro-
vide a compelling case for possible underuse. never-
theless, the mean size of resected tumors in our study 
increased from 1.8 cm in 2002 to 3.9 cm in 2012, in-
dicating that positive outcomes of prior operations and 
accumulated surgical experience allowed us to resect 
larger tumors rather than perform radical surgery. 
Fig. 8. Annual rates of patients undergoing radical neph-
rectomy and partial nephrectomy for benign tumors only.
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despite vast improvements in modern imaging, 
between 16.4% and 23% of patients following surgi-
cal resection of a suspect renal mass will have a be-
nign lesion such as angiomyolipoma, oncocytoma, 
metanephric adenoma or hemorrhagic cyst15,16, and in 
these cases radical surgery is not justified. Although 
percutaneous renal biopsy can be performed using 
CT guidance with ease, differentiation between be-
nign and malignant tumor or determination of tumor 
histologic subtypes by current radiologic and biopsy 
techniques alone or in combination has only 60%-
70% accuracy17. in 2012, we succeeded in reducing the 
number of patients undergoing rn for benign tumors 
to less than one quarter compared to 2002. The rate of 
unnecessary rn for benign tumors was reduced im-
pressively from 85.7% to 23.1%. it is as important to 
note that 26% of patients with rCC have a clinically 
unsuspected chronic kidney disease. for this group 
of patients, overaggressive surgery could result in the 
need of dialysis and/or kidney transplantation, which, 
of course, is associated with complications as well as 
resulting in the quality of life loss and substantial eco-
nomic cost18. 
in addition, just when the issue of elective Pn ap-
peared to be settled in 2002, it is now controversial 
again, with some centers proposing expansion of in-
dications to include larger tumor size. Partial nephre-
ctomy has been shown in multiple studies to be safe 
and feasible in selected patients with T1b (4-7 cm) 
renal tumors with oncologic outcomes comparable to 
rn2.
Thus, nss is an overriding theme in the manage-
ment of clinical T1 renal masses when it is considered 
technically feasible. we have accepted elective Pn as 
the standard of care for small renal masses and even 
selected patients with T1b tumors, but what about 
even larger tumors >7 cm? recent studies add to a 
growing literature suggesting that elective Pn may 
also be a reasonable option even for selected patients 
with T2 (7-10 cm) tumors19. many of these studies ac-
tually report better cancer-specific survival in patients 
with T1b and larger tumors managed with elective 
Pn when compared with rn. however, herein lays 
the problem: the expanding indications are without 
substantive supportive evidence. in most of these 
series, patients managed with elective Pn had more 
favorable tumor characteristics (tumors were periph-
erally located with no apparent involvement of the 
collecting system, perinephric fat, or venous struc-
tures on preoperative imaging), indicating significant 
selection bias. most series were single center, retro-
spective and nonrandomized; cohorts were small and 
often unmatched. nowadays, as a standard elective 
method of treatment, Pn is recommended only for 
T1 tumors20. According to the recent european As-
sociation of urology guidelines, Pn for larger tumors 
(T2) remains a method the implementation of which 
should be considered but is not a standard treatment 
of choice20.
so, what are the reasons not to abandon the basic 
principles of robson’s radical surgery? elective Pn for 
patients with T1b and larger tumors remains contro-
versial for a variety of reasons. The risk of malignancy 
is higher and larger tumors are more likely to have 
negative prognostic indicators such as higher tumor 
grade, necrosis, and T stage. Therefore, the number 
of cases for which Pn is beneficial due to benign pa-
thology will naturally be lower21. The risk of systemic 
metastasis is also directly related to tumor size, and 
many patients have micro metastases at the time of 
surgery21. obviously, the management of local tumor 
will not affect outcome in this case. The incidence of 
multicentricity appears to increase with larger tumor 
size and accounts for most local recurrences after Pn22. 
local recurrence rates after Pn ranged from 4% to 
6%, except when restricted to smaller tumor size, and 
this is a potential benefit of rn for larger tumors14. 
Another concern regarding elective Pn in patients 
with T1b and larger tumors relates to the increased 
perioperative morbidity reported in all recent series23. 
Taking all of these considerations into account, we 
have to be very prudent when recommending elective 
Pn for large and technically demanding tumors. our 
current perspective is that only highly selected and 
well-counseled patients should be considered for elec-
tive Pn for tumors sized >7 cm23.
The ultimate solution to this form of dilemma is 
analysis of a properly powered randomized prospec-
tive clinical trial. in 2011, the european organiza-
tion for research and Treatment of Cancer (eorTC) 
reported results from a prospective phase 3 trial ran-
domizing patients with solitary renal lesions 5 cm and 
a normal contralateral kidney to Pn or rn24. sur-
prisingly, the results clearly showed that Pn was not 
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superior to rn in terms of cancer specific and overall 
survival. we have level 1 evidence that Pn is not su-
perior to rn for tumors <5 cm. The choice of treat-
ment for the patient with localized rCC needs to be 
individualized. Preservation of renal function without 
compromising the oncologic outcome should be the 
most important goal in the decision-making process.
Conclusions
surgery still remains the only curative approach 
for localized rCC. during the study period, kidney 
tumors shifted significantly to more organ-confined 
stages due to a widespread use of imaging techniques. 
our data also argue strongly that indications for Pn 
related to tumor size should be expanded and not re-
stricted. with a time delay, our findings are consistent 
with trends observed at several well-known academic 
institutions. when choosing between rn and Pn, 
one should consider the location, radiologic character-
istics, individual patient attributes and technical abili-
ties available, not only tumor size. The maximum size 
of tumors treatable with rn remains controversial. 
we have to be very cautious in recommending elec-
tive Pn for larger tumors. The expanding indications 
are still without substantive supportive evidence and 
we have level 1 evidence that Pn is not superior to 
rn in terms of overall and cancer specific survival24. 
robson’s principles have been partially deserted over 
the last decade, however, proving that Pn is superior 
to rn in terms of cancer specific and overall survival 
for larger tumors remains to be seen.
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sažetak
rAZvoJ PArCiJAlne nefrekTomiJe Zbog TumorA bubregA – nAPuŠTAmo li osnovnA 
nAČelA robsonove rAdikAlne nefrekTomiJe?
G. Štimac, A. Reljić, I. Pezelj, I. Grubišić, D. Justinić, Š. Šoip, I. Svaguša i D. Trnski
Prije 50 godina robson je izveo prvu radikalnu nefrektomiju (rn) te time postavio zlatni standard za kirurško liječe-
nje tumora bubrega. iskustvo je pokazalo da je parcijalna nefrektomija (Pn) jednako učinkovita s prednostima očuvanja 
bubrežne funkcije i izbjegavanjem nepotrebne nefrektomije zbog dobroćudnih tumora. u radu se prikazuju promjene 
kliničke slike i napredak u izboru operativnog liječenja tumora bubrega na našoj klinici, naglašavajući razvoj indikacija za 
primjenu Pn. studija je obuhvatila sve bolesnike koji su operativno liječeni zbog tumora bubrega na našoj klinici u 2002., 
2007. i 2012. godini. Analizirali smo izbor operativne metode u danim razdobljima prema veličini tumora, stadiju bolesti 
i dijagnozi.u promatranom razdoblju porastao je udio tumora T1, s 46,6% u 2002. na 69,8% u 2012. godini. od ukupnog 
broja operiranih bolesnika u 2002. godini 2,7% ih je operirano metodom Pn, dok je u 2012. taj udio bio 32%, što predstav-
lja porast veći od 10 puta. Porast godišnjeg udjela Pn za stadij bolesti T1 bio je još veći, sa 6,6% u 2002. na 46,7% u 2012. 
godini. Za razliku od skupine rn, u skupini Pn zabilježen je porast prosječne veličine tumora s 1,8 cm u 2002. na 3,9 
cm u 2012. godini. impresivno je smanjenje rn kod bolesnika s dobroćudnom patologijom koja je u 2002. godini iznosila 
85,7%, a u 2012. samo 23,1%. rezultati našega istraživanja pokazuju da indikacije za Pn treba proširivati, a ne ograniča-
vati. u zadnjih 10 godina robsonova načela su djelomice napuštena, ali superiornost Pn nad rn tek treba dokazati. 
ključne riječi: Bubrežni tumori – kirurgija; Karcinom, bubrežne stanice – kirurgija; Nefrektomija – metode; Organi, poštedno 
liječenje; Ishod zdravstvene skrbi – ocjena
